Reblozyl is used to treat transfusion-dependent anemia in adults with beta-thalassemia, myelodysplastic syndromes (MDS), myelodysplastic syndromes with ring sideroblasts (MDS-RS), or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). It is administered as a subcutaneous injection by a healthcare provider once every 3 weeks.